Herantis Pharma Plc's first clinical study for people with Parkinson's with the company's investigational product CDNF has proceeded to its first CDNF safety assessment study. 

CDNF is a novel drug candidate for the treatment of neurodegenerative diseases including Parkinson's. CDNF is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties. It is patented internationally by Herantis.

Recruitment is opening at two new study sites: Helsinki University Hospital in Finland, and Skåne University Hospital in Lund, Sweden. The first study site, Karolinska University Hospital in Stockholm, Sweden continues to recruit additional people with Parkinson's. The randomized, placebo-controlled clinical study of CDNF intends to recruit in total 18 people with Parkinson's. Those participating will also be offered a possibility to participate in an extension study in which all participants will receive CDNF treatment, subject to regulatory approval of the extension study.

Helen Matthews, Deputy CEO The Cure Parkinson's Trust, said:

It is encouraging to read that this trial of a new growth factor has reached this important milestone and can now go on to recruit 18 further people with Parkinson's.  We look forward to hearing progress in due course.

Read more about the study here.

Excerpts above taken from online GlobeNewswire.